Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp409 | Paediatric bone disease | ECTS2014

Ibandronate in the treatment of pediatric osteoporosis

Kutilek Stepan , Plasilova Ivana

Background: Orally administered ibandronate is an effective agent in the treatment of postmenopausal osteoporosis. There are only scarce data regarding its use in children with impaired bone health.Objectives: To evaluate the effect of oral ibandronate on bone health in osteoporotic children and adolescents.Patients, materials and methods: We enrolled six patients (all boys; mean age 15.7±3.8 years; range 8–18 years) with...

ba0007p6 | (1) | ICCBH2019

Pseudohypoparathyroidism type Ib initially masquerading as epileptic seizures due to Fahr's disease

Kutilek Stepan , Plasilova Ivana

Background: Hypocalcaemia can be manifested by paresthesia, muscle cramps, muscle weakness, syncope, convulsions and even severe psychomotor retardation. Suchs symptoms can be initially considered as signs of epilepsy. Fahr’s disease is neurological disorder with neuropsychic changes and convulsions. Fahr’s disease is characterized by central nervous system calcifications caused by mutations in SLC20A2 gene, encoding sodium-dependent phosphate transporter 2 (PiT-2) t...

ba0004p80 | (1) | ICCBH2015

Ibandronate in the treatment of pediatric osteoporosis

Kutilek Stepan , Plasilova Ivana , Langer Jan

Objectives: To evaluate the effect of oral ibandronate on bone health in osteoporotic children and adolescents, as there are only scarce data regarding its use in pediatric population.Patients, materials, methods: We enrolled seven patients (six boys; one girl; mean age 15.3±3.8 years; range 8–18 years) with low bone mineral density (BMD) (mean 0.746±0.141 g/cm2; i.e. −3.3±1.5 S.D. z-score) and...

ba0007p135 | (1) | ICCBH2019

Oral ibandronate therapy in patients with osteogenesis imperfecta

Kutilek Stepan , Skalova Sylva , Plasilova Ivana

Background: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children/adolescents, and in patients with osteogenesis imperfecta (OI), as bisphosphonates are off-label drugs in pediatrics.Case presentation: We present two patients with OI type I (14 year o...

ba0004p84 | (1) | ICCBH2015

Different causes of infantile hypercalcemia

Kutilek Stepan , Plasilova Ivana , Gut Josef , Konrad Martin , Schlingman Karl P , Machata-Hanulikova Kristyna , Teterova-Cerna Hana

Background: Hypercalcemia in childhood is rare, can be of various origin and might go unrecognized until severe signs appear. We demonstrate hypercalcemia of different causes in two infants.Case no 1.: 5-month old girl with failure to thrive, constipation, muscle hypotonia, dehydration, where total calcaemia peaked to 4.25 mmol/l. Low calcium diet, application of glucocorticoids and furosemide resulted in a drop in calcaemia to values below 3 mmol/l and ...